Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.

Journal of Managed Care & Specialty Pharmacy
Anna OhLeslie Wilson

Abstract

The approval of new immunotherapies has dramatically changed the treatment landscape of metastatic melanoma. These survival gains come with trade-offs in side effects and costs, as well as important considerations for third-party payer systems, physicians, and patients. To develop a Markov model to determine the cost-effectiveness of nivolumab, ipilimumab, and nivolumab-ipilimumab combination as firstline therapy in metastatic melanoma, while accounting for differential effectiveness in programmed death-ligand 1 (PD-L1) positive and negative patients. A 3-state Markov model (PD-L1 positive stable disease, PD-L1 negative stable disease, and progression and/or death) was developed using a U.S. societal perspective with a lifetime time horizon of 14.5 years. Transition probabilities were calculated from progression-free (PF) survival data reported in the CheckMate-067 trial. Costs were expressed in 2015 U.S. dollars and were determined using national sources. Adverse event (AE) management was determined using immune-related AE (irAE) data from CheckMate-067, irAE management guides for nivolumab and ipilimumab, and treatment guidelines. Utilities were obtained from published literature, using melanoma-specific studies when availabl...Continue Reading

References

Jan 1, 1985·Medical Decision Making : an International Journal of the Society for Medical Decision Making·P DoubiletB J McNeil
Mar 1, 1985·American Journal of Clinical Pathology·J P NolanG DiBenedetto
Oct 9, 1996·JAMA : the Journal of the American Medical Association·L B RussellM C Weinstein
Jul 23, 2003·Statistics in Medicine·Jun Shao, Bob Zhong
Mar 9, 2004·Health Affairs·Peter J Neumann
Apr 16, 2004·The Journal of Investigative Dermatology. Symposium Proceedings·Suephy C ChenMary K Goldstein
Sep 13, 2006·British Journal of Cancer·A LloydJ Watkins
Oct 28, 2006·PharmacoEconomics·Milton C Weinstein
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Mar 1, 2012·Journal of Medical Economics·P SwinburnA Lloyd
Sep 25, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·David M EddyUNKNOWN ISPOR−SMDM Modeling Good Research Practices Task Force
Oct 20, 2012·American Journal of Preventive Medicine·Gery P GuyLisa C Richardson
Mar 30, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Don HusereauUNKNOWN ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Jul 30, 2014·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Darren M PalathinkalJeremy S Bordeaux
Aug 28, 2014·The New England Journal of Medicine·Peter J NeumannMilton C Weinstein
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfJedd D Wolchok
Mar 10, 2015·Molecular Immunology·Abhisek SwaikaRichard W Joseph
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Apr 22, 2015·The New England Journal of Medicine·Michael A PostowF Stephen Hodi
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Sep 16, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J NaidooJ D Wolchok
Sep 26, 2015·The European Respiratory Journal·Claudia C DoblerGuy B Marks
Nov 13, 2015·JAMA Oncology·Aaron R Hansen, Lillian L Siu
Apr 10, 2016·Journal of the National Comprehensive Cancer Network : JNCCN·Daniel G CoitAnita Engh
Jul 2, 2016·JAMA Oncology·Claire F FriedmanMichael A Postow
Jan 1, 2015·The Journal of Economic Perspectives : a Journal of the American Economic Association·David H HowardRena M Conti

❮ Previous
Next ❯

Citations

Jul 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine G KohnChristopher R Flowers
Nov 28, 2018·Journal of Surgical Oncology·Minyoung KwakGeorgia M Beasley
Jan 20, 2018·Current Oncology Reports·Mellar P Davis, Rajiv Panikkar
Feb 20, 2018·Experimental Hematology & Oncology·Charles McCreaJustin Doan
Apr 5, 2019·Journal of Managed Care & Specialty Pharmacy·Andrew J KlinkFrank Xiaoqing Liu
May 8, 2019·Cancers·Sebastian ChrétienTheodoros Foukakis
Jan 19, 2020·International Journal of Molecular Sciences·Sanna Iivanainen, Jussi P Koivunen
Nov 26, 2019·PharmacoEconomics·Claire GorryMichael Barry
Jan 29, 2020·PharmacoEconomics Open·Mikyung Kelly SeoJohn Cairns
Aug 1, 2019·Expert Review of Clinical Pharmacology·Regina KrattingerReinhard Dummer
Nov 11, 2019·Journal of General Internal Medicine·Adewole S AdamsonMichael P Pignone
Apr 2, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rahul SethPauline Funchain
Sep 10, 2020·Biomedicines·Fleury Augustin Nsole BitegheStefan Barth
Sep 21, 2020·Annals of Surgical Oncology·Hayley StandageDale Han
Jul 18, 2020·Cancer Immunology, Immunotherapy : CII·Charlotte CouchoudVirginie Nerich
Nov 24, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Pol Specenier
Jun 21, 2021·Archivum Immunologiae Et Therapiae Experimentalis·Rodrigo Kern, Carolina Panis
Sep 14, 2021·Frontiers in Pharmacology·Xiaomin WanChongqing Tan
Dec 3, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sarah A Weiss, Harriet Kluger

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.